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ABSTRACT
Objective Hospice/palliative care patients may
differ from better studied populations, and data
from other populations cannot necessarily be
extrapolated into hospice/palliative care clinical
practice. Pharmacovigilance studies provide
opportunities to understand the harms and
benefits of medications in routine practice.
Gabapentin, a γ-amino butyric acid analogue
antiepileptic drug, is commonly prescribed for
neuropathic pain in hospice/palliative care. Most
of the evidence however relates to non-
malignant, chronic pain syndromes (diabetic
neuropathy, postherpetic neuralgia, central pain
syndromes, fibromyalgia). The aim of this study
was to quantify the immediate and short-term
clinical benefits and harms of gabapentin in
routine hospice/palliative care practice.
Design Multisite, prospective, consecutive
cohort.
Population 127 patients, 114 of whom had
cancer, who started gabapentin for neuropathic
pain as part of routine clinical care.
Settings 42 centres from seven countries. Data
were collected at three time points—at baseline,
at day 7 (and at any time; immediate and short-
term harms) and at day 21 (clinical benefits).
Results At day 21, the average dose of
gabapentin for those still using it (n=68) was
653 mg/24 h (range 0–1800 mg) and 54 (42%)
reported benefits, of whom 7 (6%) experienced
complete pain resolution. Harms were reported
in 39/127 (30%) patients at day 7, the most
frequent of which were cognitive disturbance,
somnolence, nausea and dizziness. Ten patients
had their medication ceased due to harms. The
presence of significant comorbidities, higher
dose and increasing age increased the likelihood
of harm.
Conclusions Overall, 42% of people
experienced benefit at a level that resulted in
continued use at 21 days.
BACKGROUND
Pain is a common concern of patients
receiving hospice/palliative care. While it
is possible for pain in many people to be
well managed with simple analgesics and/
or opioids,1 a proportion of patients
experience neuropathic pain. Neuropathic
pain has been defined by the International
Association for the Study of Pain (IASP) as
“pain caused by a lesion or disease of the
somatosensory system.”2 Adjuvant analge-
sics are commonly recommended for the
management of neuropathic pain.1 3–5 A
wide array of adjuvant drug choices are
available from within several main classes:
the ones most commonly used are antide-
pressants and antiepileptics.
Gabapentin was originally approved in
1993 as an antiepileptic for treatment of
complex partial seizures.6 It was devel-
oped as an analogue of γ-aminobutyric
acid. Its site and mode of action in neuro-
pathic pain are thought to be via modula-
tion of the α and δ calcium channel
subunits.6 7 Gabapentin is water soluble
with a very high volume of distribution
and is not metabolised but rather
excreted unchanged in the urine at a rate
proportional to creatinine clearance,
requiring dose reduction in people with
renal impairment.8 Plasma concentrations
are proportional to the dose administered
at doses up to 1800 mg/day. However, at
higher doses, drug absorption becomes
saturated, resulting in an effective dose
‘ceiling’ and adding to variability
between patients. Its elimination half-life
is 5–9 h.
Potential harms documented in the lit-
erature include: dizziness (21%), somno-
lence (16%), peripheral oedema (8%)
and gait disturbance (9%), although
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serious adverse events (4%) were reported to be no
more common than placebo.9 Adverse drug reactions
reported to the French Pharmacovigilance System
most commonly included neuropsychiatric symptoms,
but hepatic problems were also noted.10 The evidence
collected in such a database is very likely to under-
represent the incidence of adverse effects, as in usual
clinical practice only the most severe problems are
commonly reported.
Prescribing practice in hospice/palliative care has
been extrapolated from related areas of clinical prac-
tice with populations that are more readily studied.
For instance, much of the available data for the effi-
cacy of gabapentin is derived from studies in chronic
pain syndromes such as diabetic or postherpetic
neuropathic pain.11 The efficacy reported in the litera-
ture for gabapentin in the two best studied neuro-
pathic conditions is: (A) to achieve a greater than
50% pain reduction for painful diabetic neuropathy:
33% response rate with a number needed to treat
(NNT) of 5.8 (4.3–9.0) and an associated placebo
response rate of 23%, at doses of between 600 and
3600 mg/day5; and (B) to achieve a 50% pain reduc-
tion for postherpetic neuralgia: a response rate of
33% with an NNT of 7.5 (5.2–14) and a placebo
response rate of 20%, at doses of 1800–3600 mg/
day.5 On the basis of evidence that includes the avail-
able data and the risk/benefit profiles and availability
of gabapentin and alternative adjuvants, current
guidelines for the management of neuropathic pain
suggest gabapentin as one of the first-line treatment
options.3 4 12
Owing to the limited available evidence, an inter-
national initiative was started in 2011 to improve clin-
icians’ understanding of the net clinical effects of key
medicines used in hospice/palliative care and to
further inform prescribing in this important area of
patient care.13 This is part of expanding the evidence
base for clinical care by the Australian Palliative Care
Clinical Studies Collaborative (PaCCSC). The general
rationale and methodology for these studies have been
reported previously.14
The aim of this study was to describe the net clinical
effect (ie, the overall benefits and the immediate and
short-term harms) of gabapentin when prescribed for
neuropathic pain in a consecutive, prospective cohort
of hospice/palliative care patients in a variety of clin-
ical settings where the medication was started as part
of routine clinical care. The null hypothesis was that
there would be no clinicodemographic factors that
predict benefit or separately harms.
METHODS
All participating sites received ethical waivers (as the
work falls under quality assurance, quality improve-
ment, performance monitoring and/or clinical audit
study type) or approval for low-risk research. The
study involved only the collection of routine data by
treating clinicians already involved in the care of the
patient, using data which are, or should be, routinely
collected in order to monitor treatment outcomes,
and precautions were taken to ensure non-
identifiability of all data entered into the RAPID study
(for instance, by the use of age rather than date of
birth). Patients’ and/or family members’ consent was
therefore not required for the study.
The study methods have been described in detail
previously.13 14 An expert committee defined prespe-
cified clinical benefit and harm fields based on the
available literature relating to the use of gabapentin
for neuropathic pain, selecting time points for benefits
and harms according to its profile of action. The
National Cancer Institute’s Common Toxicity Criteria
for Adverse Events (NCI CTCAE v4) Likert scales for
grading effects were used.15 Non-identifying demo-
graphic and clinical data were entered pro forma
using a 128-bit encrypted web portal (http://www.
caresearch.com.au). Data were recorded on consecu-
tive patients at participating clinical sites.
Data were recorded at three set time points: at base-
line (the index symptom, and symptoms that could
reflect harm subsequently from the medication); at
day 7 (immediate and short-term harms); and at day
21 (index symptom (neuropathic pain response) after
starting gabapentin; figure 1). The NCI CTCAE for
neuropathic pain ask the clinician to rate the overall
severity of the symptoms, including also their impact
on activities of daily living. This approach was chosen
as the intention was to quantify the degree of impact
from a symptom perspective, and to align the assess-
ment approaches of benefits and harms.
Overall benefit was defined as a one point reduction
in the NCI CTCAE (eg, severe to moderate, moderate
to mild, mild to none). Harms were attributed to
gabapentin if the criteria for NCI CTCAE were
greater than the patient’s baseline measurement at or
before day 7. For harms rated as 3 or greater on the
NCI CTCAE at day 7, data were collected on the
modified Naranjo scale.16 The Naranjo questionnaire
is designed to aid in determining attribution of an
adverse drug reaction to the drug itself. The Naranjo
score was modified for the hospice/palliative care
setting and to facilitate consistency between patients.
Questions 2, 3, 5, 9 and 10 were reported, along with
the dose at the time of the toxicity (table 1). Other
items, such as rechallenge with the medication, were
excluded as the information could not be obtained for
the majority of palliative care patients.16 Functional
status was recorded using the Australian modified
Karnofsky Performance Scale, and comorbidities were
assessed using the unweighted Charlson Comorbidity
Index.17 18
Statistical methods
T tests, Mann–Whitney U tests and χ2 tests were used
to test for differences between groups for continuous
Research
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and categorical variables as appropriate. Univariable
logistic regression model for each outcome on key
clinical and demographic parameters was undertaken,
clustering over site to account for correlated readings.
Additionally, logistic regression was performed for
each outcome on each pair of key parameters and
their product term to identify possible subgroups that
were associated with the outcomes. We used multiple
imputations to account for missing data, with 20
resamples drawn for a sensitivity analysis. Results are
reported as ORs with 95% CIs. No adjustment was
made for multiple comparisons, as the results are
Figure 1 Gabapentin pharmacovigilance study flow chart (NR, not reported).
Table 1 Modified Naranjo scores for toxicities grade 3 or higher on the NCI CTCAE
Patient
















A 200 2 0 −1 0 0 1 Possible
B 200 2 1 −1 0 0 2 Possible
C 100 2 1 −1 0 0 2 Possible
D 300 2 1 −1 0 0 2 Possible
E 200 2 0 −1 0 0 1 Possible
F 200 2 1 2 0 0 5 Probable
G 1200 2 0 −1 0 0 1 Possible
Median dose 200 mg/day, with a range of 100–1200 mg/day.
Q2: Did the adverse event occur after the suspected drug was administered?
Q3: Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered?
Q5: Are there alternative causes (other than the drug) that could have on their own caused the reaction?
Q9: Did the patient have a similar reaction to the same or similar drugs in any previous exposure?
Q10: Was the adverse event confirmed by any objective evidence including clinician observation.
*According to modified Naranjo checklist.
ADR, adverse drug reaction; NCI CTCAE, National Cancer Institute’s Common Toxicity Criteria for Adverse Events.
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considered to be hypothesis generating. All models
were validated using the Hosmer-Lemeshow goodness
of fit test. A two-tailed p value less than 0.05 is con-
sidered statistically significant. Data were imported
into Excel (Microsoft Corp, Seattle, Washington, USA,
2006). All analyses were performed in STATA SE
V.12.1 (Statacorp, Texas, USA).
RESULTS
The clinical and demographic data of the study parti-
cipants are shown in table 2. Data were available for
127 patients from 42 hospice/palliative care sites in
seven countries (table 3) collected between September
2012 and August 2013. Clinical sites were drawn
from consultative services, ambulatory clinics and spe-
cialist inpatient hospice/palliative care units, reflecting
the scope of current specialist hospice/palliative care
practice in the participating countries. In this sample,
the majority (89.7%) of patients had cancer. The
mean NCI CTCAE score for neuropathic pain at base-
line was 2.33. Baseline symptoms are recorded in
table 4. Of note, the rates of fatigue (60%), somno-
lence (42%), cognitive disturbance (23%) and dizzi-
ness (16%) were all high at baseline.
At day 21 (the time point for assessment of clinical
benefits), 14 (11%) patients had died, 44 (35%) had
no data recorded (usually because they were
community-based patients with no clinical contact
around that time point), and an overall symptom
score was documented in 69/127 patients (table 5). Of
these, 54 (78% of patients where data were available)
experienced an improvement in their pain. At day 21,
68 were still on regular gabapentin, and were receiv-
ing an average of 653 mg of gabapentin/24 h (SD
402; median 600 mg; range 100–1800 mg).
A total of 39/122 surviving patients had harms
recorded (32%; CI 23.6% to 40.4%; table 6) and
they recorded 11 different harms, but information
about harms was not recorded for almost half of our
sample (n=56). The most frequently encountered
harms were somnolence (n=24, 26% of harms), cog-
nitive disturbance (n=19, 20% of harms) and fatigue
(n=14, 15% of harms). Ten patients had their medica-
tion ceased for harms which included cognitive dis-
turbance, somnolence, nausea and dizziness, while for
19 patients the gabapentin dose was reduced (table 7).
Eleven patients were prescribed a medication to treat
toxicity, while nine experienced a harm of grade 3 or
higher. Of these, seven were assessed using the modi-
fied version of the Naranjo scale, and two were
excluded because the harm was recorded as not occur-
ring after the administration of gabapentin. The total
number of patients who received benefit from gaba-
pentin without experiencing any harms was 12
(9.4%).
Multiple imputation on the outcome ‘harm’
revealed that a higher Charlson Comorbidity Index
was associated with an increase in the likelihood of
Table 2 Baseline clinical and demographic data
n (%) Median Range Mean SD
Age 127 (100) 68 63 (26–89) 66.2 12.6
Gender (male) 47 (80)
Australian-modified Karnofsky Performance Status Score 126 (99) 60 70 (20–90) 56.7 15.7
Body mass index 101 (80) 23.7 20 (13.9–33.9) 24.1 4.1
C reactive protein 32 (25) 76.5 378 (5–383) 102.2 85.9
Calculated creatinine clearance 71 (56) 70 239.1 (0.9–240) 74.5 36.4
National Cancer Institute Common Toxicity Grading for Pain 127 (100) 2 2 (1–3) 2.33 0.64
Primary life-limiting illness
Cancer 121 (95.3)
End-stage renal disease 2 (1.6)
End-stage respiratory disease 1 (0.8)
Other (severe peripheral vascular disease (1), unrecorded (2)) 3 (2.4)











Metro 5 (12) 9 (21) 7 (17) 4 (10) 4 (10) 29 (70)
Non-metro 3 (7) 3 (7) 2 (5) 2 (5) 3 (7) 13 (30)
Total 8 (19) 12 (29) 9 (21) 6 (14) 7 (17) 42 (100)
Participating countries—Australia, Canada, Hong Kong, the UK, Italy, India, New Zealand.
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experiencing a harm (OR=1.97; CI 1.16 to 3.36;
p=0.013). In the logistic regression analyses, there
was a significant interaction between daily gabapentin
dose (in increments of 100 mg/day) and each add-
itional year of age on those experiencing harm
(OR=1.20 (1.03 to 1.39), p=0.017), but this effect
attenuated (OR=1.02 (p=0.22)) when the outcomes
for harm were imputed for missing data. Subgroup
analysis on the crude data indicated that among those
experiencing a higher dose (300 mg/day or greater),
10/14 of those greater than mean age (of 65 years)
experienced harm versus 4/13 of those less than mean
age who experienced harm (p=0.035).
DISCUSSION
Gabapentin is a common adjuvant pain medication,
which has an indication for neuropathic pain. The
reported NNTs in the literature range from 5.8 to 7.5,
and it has been highlighted previously that in cancer
pain, as experienced by the majority of our sample, the
number needed to harm (NNH) is lower and the NNT
higher than in other pain populations.19 In compari-
son, in this unselected hospice/palliative care popula-
tion with significant pain, benefit was reported in 42%
of people at 21 days. However, the rates of harm were
also higher than those reported in the literature, with
30% of the hospice/palliative care population experi-
encing one or more harms, 9 (7%) of which were rated
as ‘severe’. The most common harms in the hospice/
palliative care population—somnolence, cognitive dis-
turbance and fatigue—appear to be more frequent
than those reported in the literature. The contribution
of disease progression, gabapentin or both to the
experience of fatigue that had worsened since the start
of medication cannot be separated in a cohort study
and instead requires the use of controlled studies. In
previous pharmacovigilance reports in this hospice/pal-
liative care population (eg, for haloperidol in delir-
ium20), the presence of significant comorbidities
appears to increase the risk that a patient will experi-
ence a harm. Only 9% of patients benefited without
also experiencing any harm. As in previous studies,
baseline data (table 3) reveal a pattern of high rates of
relevant symptomatology in this patient group which,
if not documented prior to starting gabapentin, could
be misattributed to the medication under study.






Fatigue 76 (60) 2 1–3
Dizziness 20 (16) 1 1–3
Somnolence 53 (42) 1 1–3
Cognitive disturbance 29 (23) 2 1–3
Ataxia 11 (9) 1 1–5
Tremors 5 (4) 1 1–3
Nystagmus 0 (0) 0 0
Headache 7 (6) 2 1–3
Nausea 28 (22) 1.5 1–3
Suicidal ideation 4 (3) 2 1–3
Other 25 (20) 2 1–3
*Patients could have more than one symptom.
†National Cancer Institute Common Toxicity Criteria (NCI CTC).
Table 5 Outcomes at 21 days after starting gabapentin for neuropathic pain in palliative care patients (n=127)
NCI CTCAE* neuropathic pain score at
baseline (T0) before starting gabapentin
1 2 3
Subtotals (n) 12 62 53
NCI CTCAE* neuropathic pain score at 21 days (T1) after starting gabapentin 0 7 1 improved 6 improved 0 improved
1 32 2 unchanged 20 improved 10 improved
2 28 2 worsened 9 unchanged 17 improved
3 2 0 worsened 0 worsened 2 unchanged
5 14† 3 6 5
NR 44 4 21 19
Within 21 days of starting gabapentin, pain scores
Improved n=54 (42.2%) of whom 7 (5.5%) had a total pain resolution.
Doses at day 21 (mg): mean 590.6, SD 380.8, median 600, range 0–1800.
Unchanged n=13 (10.2%).
Doses at day 21 (mg): mean 707.7, SD 499.9, median 600, range 0–1800.
Worsened n=2 (1.6%), and 14† (11%) died.
Doses at day 21 (mg): mean 600, SD 300, median 600, range 300–900.
*NCI CTCAE v3 National Cancer Institute’s Common Toxicity Criteria for Adverse Events—pain scale.
0. None.
1. Mild pain.
2. Moderate pain; limiting instrumental activities of daily living (ADL).
3. Severe pain; limiting self-care ADL.
5. Death.
†The 14 deaths were excluded from the statistics.
NR, not recorded.
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Finally, it is unclear to what extent the speed of
titration of gabapentin in this population may also
contribute to its adverse effect profile, and whether
this medication is titrated differently in a population
with neuropathic cancer pain and a shorter life
expectancy than it is in the better-studied chronic
non-malignant pain population.
Limitations
The primary outcome is a clinician-rated tool for
neuropathic pain used most frequently for the evalu-
ation of chemotherapy-induced symptoms.
Patient-defined tools can be used in formal studies
where consent is sought, but are not feasible for phar-
macovigilance using data from routine clinical practice
across multiple settings and countries. The substantial
number of patients (35%) for whom no score was
reported at day 21—a time point that was selected as
being clinically meaningful—and the death of 11% of
patients within the period of the data collection
reflect the great difficulties of studying this popula-
tion. Ten people died by day 21 in this cohort and,
given that key studies in neuropathic pain in settings
such as diabetic neuropathy titrated the dose over a
4-week period, one question is whether prognostica-
tion should be considered before selecting gabapentin
over alternative analgesics.21 Although prognostication
is difficult and has a large subjective component,22 it
is important when using medications that take longer
periods of time to deliver clinical benefit. The balance
of timeliness and efficacy is an ongoing question in
palliative care.
No information on harms was given on almost half
the sample. Given the rate of attrition of patients
from this study, the use of intention-to-treat analysis
may well underestimate both the clinical benefits and
harms in this population, while the ability to identify
longer term benefits and harms is also limited.
Table 6 Overall effect
New harm
N, % (95% CI) Action following harm
Benefit
N (%)
Benefit/s (1 point NCI* reduction)
N, % (95% CI)
Yes n=39
32.0 (23.6 to 40.4)
Dose reduction 1 (0.8) Yes n=14/39
40.0 (22.9 to 57.1)No change in med 7 (5.7)
Toxicity treat—other 2 (1.6)
Other medication 3 (2.4)
NR 1 (0.8)
Dose reduction 1 (0.8) No n=6/39
17.1 (4.05 to 30.3)No change in med 1 (0.8)
Toxicity treat—other 1 (0.8)
NR 3 (2.4)
Medication cessation 4 (3.1) NR n=15/39
42.9 (25.6 to 60.1)Dose reduction 2 (1.6)
No change in med 3 (2.4)
Toxicity treat—other 2 (1.6)
Other medication 1 (0.8)
NR 3 (2.4)
Dose reduction 1 (0.8) Died n=4/39
No change in med 1 (0.8)
Toxicity treat—other 1 (0.8)
Other medication 1 (0.8)
No n=27
22.1 (14.7 to 29.6)
Dose reduction 1 (0.8) Yes n=12/27
46.2 (25.6 to 66.7)Toxicity treat—other 1 (0.8)
NR 10 (8.2)
NR 6 (4.9) No n=6/27
23.1 (5.7 to 40.4)
No change in med 1 (0.8) NR n=8/27
30.1 (11.8 to 50.0)NR 7 (5.7)
No change in med 1 (0.8) Died n=1/27
NR n=56
45.9% (36.9% to 54.9%)
28 (23) Yes n=28/56
53.8 (39.8 to 67.9)
3 (2.4) No n=3/56
5.8 (−0.8 to 12.3)
21 (17.2) NR n=21/56
40.4 (26.6 to 54.2)
4 (3.3) Died n=4/56
Died prior to assessment of harms
n=5†
Harms at 7 days and benefits at 21 days.
*Anon. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, V4.0, DCTD, NCI, NIH, DHHS. http://ctep.cancer.gov/
protocolDevelopment/electronic_applications/ctc.htm (accessed 28 May 2009).
†Excluded from statistical analysis.
NR, not reported.
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Data on changes in doses of opioids and other con-
current medications were not collected. A recent sys-
tematic review17 on coprescribing of opioids and
adjuvants has suggested that harms are less if opioid
doses are reduced at the time of initiation of an adju-
vant medication. It is therefore not possible to con-
sider whether changes in opioid dosage may have
contributed to these findings. As with all pharmacov-
igilance studies, this study sought to capture accurately
current clinical practice and therefore not to influence
current practice by trying to standardise the clinical
approach taken by participating clinical sites in areas
including a titration schedule. Likewise, the way that
gabapentin doses were titrated was not captured in
this study, accepting that the speed of titration is influ-
enced by both adverse effects and efficacy in this het-
erogeneous group. Finally, the definition of
‘neuropathic pain’ was also dealt with by using the
standard clinical practice of participating sites.
The NCI CTCAE only uses a three-point rating scale
without psychometric validation. This scale anchors to
the values of mild, moderate and severe, which are in
widespread clinical use and are meaningful.
Generalisability
This study has recruited patients from across a large
number of sites, the work of which can be considered
representative of palliative care across different institu-
tional settings, communities and countries. The popu-
lation, which mainly includes patients with cancer, is
consistent with that served by many hospice/palliative
care organisations.
CONCLUSIONS
Gabapentin is widely used in hospice/palliative care
clinical practice. This study of its use outside the
setting of randomised controlled trials suggests lower
response rates and higher levels of harms than in
highly selected populations. This study again highlights
the need to understand the actual performance of med-
ications as prescribed rather than simply relying on lit-
erature derived from trials in selected populations.
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Fatigue 6 2 3 3 14 (15) 2 (1–3) 0 2 7 1 3
Dizziness 3 1 5 0 9 (10) 1 (1–3) 1 3 2 1 2
Somnolence 8 2 10 4 24 (26) 1 (1–3) 3 4 11 1 3
Cognitive
disturbance
5 2 8 4 19 (20) 2 (1–3) 4 4 4 1 4
Ataxia 1 0 3 0 4 (4) 1 (1–5) 0 2 1 0 1
Tremors 0 1 2 1 4 (4) 1 (1–3) 0 2 1 1 0
Nystagmus 0 0 0 0 0 (0) 0 (0) 0 0 0 0 0
Headache 0 0 0 0 0 (0) 0 (0) 0 0 0 0 0
Nausea 2 1 4 0 7 (8) 1.5 (1–3) 1 1 2 2 1
Suicidal
ideation
0 1 0 1 2 (2) 2 (1–3) 0 0 0 1 1
Other 3 2 4 1 10 (11) 2 (1–3) 1 1 4 3 1
Total harms experienced 93* (100)
*Patients may experience more than one harm.
†Died before day 7.
NR, not reported.
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